Company intelligence / Profile preview

AbVacc Inc.

Rockville, Maryland, United Statesabvacc.com ↗

Ownership: Private
Development stage: Phase 1

Overview

AbVacc has several candidates in advanced preclinical development with some entering clinical stage in the next few years. Their Staphylococcus aureus vaccine candidate has been licensed to LimmaTech Biologics for Phase 1 clinical development in 2024[2][3].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: VaccinesMonoclonal antibodiesImmunotherapeutics
Industry: Biotech

Drug pipeline

4 assets

pan-influenza monoclonal antibody

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

NIAIDCARB-XNovo Holdings Repair Impact FundEliteImmune Corp.Scripps Research InstituteLa Jolla Institute for ImmunologyViroVax LLCUniversity of Texas Medical BranchJohns Hopkins UniversityUniversity of RochesterUniversity of MarylandWashington UniversityIntegral MolecularLimmaTech Biologics

Beyond the preview

Go deeper on AbVacc Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbVacc Inc..

Explore the full profile